Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

Publisher: John Wiley & Sons Inc

E-ISSN: 1445-5994|46|9|1054-1062

ISSN: 1444-0903

Source: INTERNAL MEDICINE JOURNAL, Vol.46, Iss.9, 2016-09, pp. : 1054-1062

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract